2016
Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model
Siefert AL, Ehrlich A, Corral MJ, Goldsmith-Pestana K, McMahon-Pratt D, Fahmy TM. Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model. Biomaterials 2016, 108: 168-176. PMID: 27636154, PMCID: PMC5049880, DOI: 10.1016/j.biomaterials.2016.09.004.Peer-Reviewed Original ResearchConceptsPathogen-associated molecular patternsAccumulation of MDSCsHyper-inflammatory responseOngoing immune responseCytokine IL-10Antigen-presenting cellsCurrent treatment strategiesInflammation-mediated diseasesLong treatment regimensSite of infectionNew World leishmaniasisCellular immunomodulationIL-17Suppressor cellsDendritic cellsIL-10Immunotherapeutic approachesChronic inflammationTreatment regimensIL-13Free CpGTreatment strategiesTherapeutic effectImmune responsePreclinical studies
2013
The role of regulatory T cells in the Leishmania (Viannia) panamensis mouse model: a target for immunotherapy. (P3091)
Ehrlich A, Castilho T, Goldsmith-Pestana K, Sparwasser T, McMahon-Pratt D. The role of regulatory T cells in the Leishmania (Viannia) panamensis mouse model: a target for immunotherapy. (P3091). The Journal Of Immunology 2013, 190: 187.17-187.17. DOI: 10.4049/jimmunol.190.supp.187.17.Peer-Reviewed Original ResearchIL-17IL-10Treg functionIL-13Mouse modelMixed Th1/Th2Ablation of TregsL. panamensis infectionsRegulatory T cellsTh1/Th2Treg suppressive functionAlternate treatment strategiesT cell proliferationAmelioration of diseaseDEREG micePanamensis infectionTreg impairmentTreg cellsAdoptive transferCpG treatmentDisease resolutionHyperinflammatory responseNaïve miceDisease progressionTreatment strategies